NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-258-2016-0-JP-06 CHIMERIC ANTIGEN RECEPTOR (CAR) THAT TARGETS CHEMOKINE RECEPTOR CCR4 AND ITS USE JP National Stage 2019-537030 Issued
NIAID E-089-2002-1-US-51 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 US DIV 15/710,672 10837003 Expired PDF
NCI E-258-2016-0-PCT-02 CHIMERIC ANTIGEN RECEPTOR (CAR) THAT TARGETS CHEMOKINE RECEPTOR CCR4 AND ITS USE PCT PCT PCT/US2017/052437 Expired
NCI E-258-2016-0-JP-08 CHIMERIC ANTIGEN RECEPTOR (CAR) THAT TARGETS CHEMOKINE RECEPTOR CCR4 AND ITS USE JP DIV 2021-003261 Abandoned
NCI E-258-2016-0-CA-04 CHIMERIC ANTIGEN RECEPTOR (CAR) THAT TARGETS CHEMOKINE RECEPTOR CCR4 AND ITS USE CA National Stage 3037518 Pending
NCI E-181-2017-0-US-01 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS US 62/560,930 Abandoned
NCI E-133-2017-0-US-01 IN VITRO GENERATION OF THYMIC ORGANOID FROM HUMAN PLURIPOTENT STEM CELLS US 62/560,908 Abandoned
NCI E-106-2015-0-US-03 DUAL SPECIFIC ANTI-CD22-ANTI-CD19 CHIMERIC ANTIGEN RECEPTORS US National Stage 15/559,485 10738116 Issued PDF
NIAID E-131-2015-2-US-07 NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE US National Stage 15/559,791 10562960 Issued PDF
NCI E-184-2009-0-KR-20 COMBINATION IMMUNOTHERAPY COMPOSITIONS AGAINST CANCER AND METHODS KR DIV 10-2017-7026393 Issued
NCI E-255-2012-0-US-04 Reversible Regulation Of Intein Activity Through Engineered New Zinc Binding Domain US DIV 15/707,588 10323235 Issued PDF
NCI E-280-2016-0-PCT-02 METHODS OF PREPARING AN ISOLATED POPULATION OF DENDRITIC CELLS AND METHODS OF TREATING CANCER USING SAME PCT PCT PCT/US2017/051981 Expired
NCI E-231-2017-0-US-01 IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN US 62/559,926 Abandoned
NCI E-280-2016-0-CA-03 METHODS OF PREPARING AN ISOLATED POPULATION OF DENDRITIC CELLS AND METHODS OF TREATING CANCER USING SAME CA National Stage 3037882 Pending
NIDCR E-036-2010-1-EP-05 Compositions and Methods For Screening For Lyme Disease EP DIV 17191338.7 Issued
NCI E-106-2014-0-SG-17 YEAST-BASED IMMUNOTHERAPY FOR CHORDOMA SG DIV 10201707608Q Abandoned
NCI E-013-2018-0-US-01 Compositions and Methods For Treating Cancer With Anti-CD19 Immunotherapy US 62/559,297 Abandoned
NIAID E-233-2015-0-US-06 Intestinal Filarial Antigens For The Development Of Filaria Vaccines US National Stage 15/558,336 10441642 Issued PDF
NIAID E-233-2015-0-CA-04 Intestinal Filarial Antigens For The Development Of Filaria Vaccines CA National Stage 2979840 Abandoned
NIAID E-251-2016-0-FR-06 METHODS OF DIAGNOSING AND TREATING CD55 DEFICIENCY, HYPERACTIVATION OF COMPLEMENT, ANGIOPATHIC THROMBOSIS AND PROTEIN LOSING ENTEROPATHY (CHAPLE), A NEWLY IDENTIFIED ORPHAN DISEASE FR EP 17784438.8 Issued
NIAID E-251-2016-0-DE-05 METHODS OF DIAGNOSING AND TREATING CD55 DEFICIENCY, HYPERACTIVATION OF COMPLEMENT, ANGIOPATHIC THROMBOSIS AND PROTEIN LOSING ENTEROPATHY (CHAPLE), A NEWLY IDENTIFIED ORPHAN DISEASE DE EP 17784438.8 Issued
NIAID E-251-2016-0-GB-07 METHODS OF DIAGNOSING AND TREATING CD55 DEFICIENCY, HYPERACTIVATION OF COMPLEMENT, ANGIOPATHIC THROMBOSIS AND PROTEIN LOSING ENTEROPATHY (CHAPLE), A NEWLY IDENTIFIED ORPHAN DISEASE GB EP 17784438.8 Issued
NIAID E-251-2016-0-EP-03 METHODS OF DIAGNOSING AND TREATING CD55 DEFICIENCY, HYPERACTIVATION OF COMPLEMENT, ANGIOPATHIC THROMBOSIS AND PROTEIN LOSING ENTEROPATHY (CHAPLE), A NEWLY IDENTIFIED ORPHAN DISEASE EP National Stage 17784438.8 Issued
NCI E-269-2010-0-IL-12 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE IL DIV 254469 Issued
NIAID E-251-2016-0-PCT-02 METHODS OF DIAGNOSING AND TREATING CD55 DEFICIENCY, HYPERACTIVATION OF COMPLEMENT, ANGIOPATHIC THROMBOSIS AND PROTEIN LOSING ENTEROPATHY (CHAPLE), A NEWLY IDENTIFIED ORPHAN DISEASE PCT PCT PCT/US2017/051413 Expired
NCI E-263-2011-0-CA-04 Pseudomonas Exotoxin A With Less Immunogenic B Cell Epitopes CA National Stage 2846608 Issued
NHGRI E-217-2007-0-US-15 N-ACETYL MANNOSAMINE AS A THERAPEUTIC AGENT US CON 15/702,529 10335426 Issued PDF
NCI E-266-2011-0-CA-04 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage CA National Stage 2848209 Issued
NCI E-039-2011-0-US-12 CHIMERIC RABBIT/HUMAN ROR1 ANTIBODIES US DIV 15/700,457 Abandoned
NEI E-050-2015-0-JP-07 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa JP National Stage 2017-547425 Issued
NIAID E-064-2015-2-US-05 MYELIN OLIGODENDROCYTE GLYCOPROTEIN, MYELIN BASIC PROTEIN, AND PROTEOLIPID PROTEIN COMPOSITIONS AND METHODS OF USE US National Stage 15/556,738 10759838 Issued PDF
NEI E-050-2015-0-US-08 RP2 AND RPGR VECTORS FOR TREATING X-LINKED RETINITIS PIGMENTOSA US National Stage 15/556,746 10646588 Issued PDF
NCI E-104-2013-0-US-04 ANTI-276 POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS US CON 15/699,419 10604583 Issued PDF
NIAID E-253-2011-3-US-13 NEUTRALIZING GP41 ANTIBODIES AND THEIR USE US DIV 15/699,902 10047148 Issued PDF
NHLBI E-211-2018-2-US-01 Methods Of Inhibiting Viruses Using Compositions Targeting TSG101-Ubiquitin Interaction US 62/555,947 Abandoned
NHGRI E-149-2017-0-US-01 Biomarkers of Organic Acidemias US 62/556,071 Abandoned
NCI E-016-2016-0-PCT-02 SYNERGISTIC ANTI-TUMOR EFFECT OF HMG PROTEIN IN COMBINATION WITH ANTI-CD4 ANTIBODY OR IMMUNE CHECKPOINT REGULATOR PCT PCT PCT/JP2017/032351 Expired
NCI E-265-2011-0-AU-14 Anti-CD22 Chimeric Antigen Receptors AU DIV 2017225049 Abandoned
NCI E-241-2016-0-US-01 Micro-Dose Calibrator US 62/554,980 Abandoned
NIAID E-228-2016-1-CN-05 Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof CN National Stage 201780066267.2 Issued
NIAID E-228-2016-1-IN-06 Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof IN National Stage 201917007726 Issued
NIAID E-228-2016-1-JP-11 Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof JP National Stage 2019-512267 Issued
NCI E-098-2015-0-US-05 DISPLAY PLATFORM FROM BACTERIAL SPORE COAT PROTEINS US National Stage 15/555,283 10813993 Issued PDF
NCI E-174-2011-0-US-24 PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC T CELL AND/OR B CELL EPITOPES US DIV 15/693,705 10428119 Issued PDF
NIAID E-228-2016-1-PCT-01 Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof PCT PCT COMB PCT/US2017/049894 Expired
NCI E-168-2011-0-US-08 METHODS AND COMPOSITIONS FOR INHIBITING POLYOMAVIRUS-ASSOCIATED PATHOLOGY US DIV 15/694,567 Abandoned
NIAID E-228-2016-1-EP-03 Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof EP National Stage 17768316.6 Pending
NIAID E-228-2016-1-CA-04 Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof CA National Stage 3035443 Pending
NIAID E-228-2016-1-BR-08 Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof BR National Stage BR112019004189-3 Pending
NIAID E-228-2016-1-SG-13 Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof SG DIV 10201912944Q Abandoned